Loading
Lung Adenocarcinoma / Computed Tomography / Lung Large Cell Carcinoma · Phase 2 Trial
ClinicalTrials.gov · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 trial registration for an active, non-recruiting study testing whether TRC102 (methoxyamine) added to concurrent chemoradiotherapy plus durvalumab improves progression-free survival in stage III non-squamous NSCLC. No results have been posted in this registry record; the study design and primary endpoint are described but no outcome data are available.
Phase 2, Interventional, Randomized, Parallel, Open label, Treatment purpose. Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8; age from 18 Years. Intervention: Arm I (methoxyamine, usual care). Compared with: Arm II (usual care) — Active Comparator. n = 42. 34 sites: United States.
This is a Phase 2 trial registration for an active, non-recruiting study testing whether TRC102 (methoxyamine) added to concurrent chemoradiotherapy plus durvalumab improves progression-free survival in stage III non-squamous NSCLC. No results have been posted in this registry record; the study design and primary endpoint are described but no outcome data are available.
No control arm definition, secondary endpoints, or safety measures are specified in the registry summary.
This record documents a trial in active recruitment status but posts no results. Clinicians should await publication of outcomes before drawing any conclusions about the efficacy or safety of TRC102 in this setting.
This is a Phase 2 trial registration with no results posted; it describes a planned interventional study testing TRC102 added to chemoradiotherapy in stage III NSCLC, designed to assess feasibility and signal before larger trials.
As stated by the source record.
Quoted from the source exactly as published.
This record documents a trial in active recruitment status but posts no results. Clinicians should await publication of outcomes before drawing any conclusions about the efficacy or safety of TRC102 in this setting.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05198830). This is a study registration, not published results. Lead sponsor: National Cancer Institute (NCI). Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 42 participants (ESTIMATED). Conditions: Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8. Interventions: DRUG: Carboplatin; DRUG: Cisplatin; PROCEDURE: Computed Tomography; BIOLOGICAL: Durvalumab; PROCEDURE: FDG-Positron Emission Tomography; PROCEDURE: Magnetic Resonance Imaging; DRUG: Methoxyamine; DRUG: Pemetrexed; RADIATION: Radiation Therapy. Primary outcome measures: Progression free survival (PFS) , From randomization to the date of the first documented event of tumor progression or death in the absence of disease progression, assessed at 12 months from randomization and up to 5 years. Brief summary: This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination usual care treatment comprised of pemetrexed, cisplatin or carboplatin, and radiation therapy followed by durvalumab works better than the usual care treatment alone to shrink tumors in patients with stage III non-squamous non-small cell lung cancer (NSCLC). TRC102 is in a class of drugs called antineoplastic agents. It blocks the ability of a cell to repair damage to its deoxyribonucleic acid (DNA) and may kill tumor cells. It may also help some anticancer drugs work better. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make DNA and may kill tumor cells. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy sources to kill tumor cells and shrink tumors. Giving TRC102 in combination with usual care treatment may be more effective than usual care treatment alone in stabilizing and lengthening survival time in patients with stage III non-squamous NSCLC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.